Poor prognosis germ-cell tumors: An unresolved challenge

Seminars in Urologic Oncology

Volumn 20, Issue 4, 2002, Pages 251-261

  Toner, Guy C ^a,b   Frydenberg, Mark ^a,b  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b MONASH MEDICAL CENTRE   (Australia)

Author keywords

Germinoma; Prognosis; Testicular neoplasms

Indexed keywords

BLEOMYCIN; CISPLATIN; ETOPOSIDE; IFOSFAMIDE; TUMOR MARKER; VINBLASTINE;

BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; GERM CELL TUMOR; HUMAN; LUNG TOXICITY; MALE; NEUROTOXICITY; OTOTOXICITY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TREATMENT INDICATION; TREATMENT OUTCOME;

GERMINOMA; HUMANS; MALE; PROGNOSIS; TESTICULAR NEOPLASMS;

EID: 0036862916     PISSN: 10810943     EISSN: None     Source Type: Journal    
DOI: 10.1053/suro.2002.36978     Document Type: Review

References (84)

1. Einhorn LH: Testicular cancer as a model for a curable neoplasm: The Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res 41:3275-3280, 1981
2. Einhorn LH: Treatment of testicular cancer: A new and improved model. J Clin Oncol 8:1777-1781, 1990
3. Bosl GJ, Motzer RJ: Testicular germ-cell cancer. N Engl J Med 337:242-253, 1997
4. Motzer RJ, Geller NL, Tan CC, et al: Salvage chemotherapy for patients with germ cell tumors. The Memorial Sloan-Kettering Cancer Center experience (1979-1989). Cancer 67:1305-1310, 1991
5. Vugrin D, Whitmore WF Jr, Golbey RB: VAB-5 combination chemotherapy in prognostically poor risk patients with germ cell tumors. Cancer 51:1072-1075, 1983
6. Germa-Lluch JR, Begent RH, Bagshawe KD: Tumour-marker levels and prognosis in malignant teratoma of the testis. Br J Cancer 42:850-855, 1980
7. Peckham MJ, Barrett A, McElwain TJ, et al: Non-seminoma germ cell tumours (malignant teratoma) of the testis. Results of treatment and an analysis of prognostic factors. Br J Urol 53: 162-172, 1981
8. Ozols RF, Ihde DC, Linehan WM, et al: A randomized trial of standard chemotherapy versus a high-dose chemotherapy reg-imen in the treatment of poor prognosis nonseminomatous germ-cell tumors. J Clin Oncol 6:1031-1040, 1988
9. Bosl GJ, Geller NL, Cirrincione C, et al: Multivariate analysis of prognostic variables in patients with metastatic testicular cancer. Cancer Res 43:3403-3407, 1983
10. Stoter G, Sylvester R, Sleijfer DT, et al: Multivariate analysis of prognostic factors in patients with disseminated nonseminomatous testicular cancer: Results from a European Organization for Research on Treatment of Cancer Multiinstitutional Phase III Study. Cancer Res 47:2714-2718, 1987
11. Birch R, Williams S, Cone A, et al: Prognostic factors for favorable outcome in disseminated germ cell tumors. J Clin Oncol 4:400-407, 1986
12. Prognostic factors in advanced non-seminomatous germ-cell testicular tumours: Results of a multicentre study. Report from the Medical Research Council Working Party on Testicular Tumours. Lancet 1:8-11, 1985
13. Droz JP, Kramar A, Ghosn M, et al: Prognostic factors in advanced nonseminomatous testicular cancer. A multivariate logistic regression analysis Cancer. 62:564-568, 1988
14. Mead GM, Stenning SP, Parkinson MC, et al: The Second Medical Research Council study of prognostic factors in nonseminomatous germ cell tumors. Medical Research Council Testicular Tumour Working Party. J Clin Oncol 10:85-94, 1992
15. Toner GC, Geller NL, Lin SY, et al: Extragonadal and poor risk nonseminomatous germ cell tumors. Survival and prognostic features. Cancer 67:2049-2057, 1991
16. Nichols CR, Saxman S, Williams SD, et al: Primary mediastinal nonseminomatous germ cell tumors A modern single institution experience. Cancer 65:1641-1646, 1990
17. Williams SD, Birch R, Einhorn LH, et al: Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med 316:1435-1440, 1987
18. Bosl GJ, Geller NL, Bajorin D: Serum tumor markers and patient allocation to good-risk and poor-risk clinical trials in patients with germ cell tumors. Cancer 67:1299-1304, 1991
19. Bajorin D, Katz A, Chan E, et al: Comparison of criteria for assigning germ cell tumor patients to "good risk" and "poor risk" studies. J Clin Oncol 6:786-792, 1988
20. International Germ Cell Cancer Collaborative Group: international Germ Cell Consensus Classification: A prognostic faclor-based staging system for metastatic germ cell cancers J Clin Oncol. 15:594-603, 1997
21. de Wit R, Roberts JT, Wilkinson PM, et al: Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3- or 5-day schedule in good-prognosis germ cell cancer: A randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council. J Clin Oncol 19:1629-1640, 2001
22. Bower M, Newlands ES, Holden L, et al: Treatment of men with metastatic non-seminomatous germ cell tumours with cyclical POMB/ACE chemotherapy. Ann Oncol 8:477-483, 1997
23. Collette L, Sylvester RJ, Stenning SP, et al: Impact of the treating institution on survival of patients with "poor-prognosis" metastatic nonseminoma. European Organization for Research and Treatment of Cancer Genito-Unnary Tract Cancer Collaborative Group and the Medical Research Council Testicular Cancer Working Party. J Natl Cancer Inst 91:839-846, 1999
24. Kollmannsberger C, Nichols C, Meisner C, et al: Identification of prognostic subgroups among patients with metastatic 'IGCCCG poor-prognosis' germ-cell cancer: An explorative analysis using cart modeling. Ann Oncol 11:1115-1120, 2000
25. Bokemeyer C, Nichols CR, Droz JP, et al: Extragonadal germ cell tumors of the mediastinum and retroperitoneum: Results from an international analysis. J Clin Oncol 20:1864-1873, 2002
26. Morris MJ, Bosl GJ: Recognizing abnormal marker results that do not reflect disease in patients with germ cell tumors. J Urol 163:796-801, 2000
27. Toner GC, Geller NL, Tan C, et al: Serum tumor marker halflife during chemotherapy allows early prediction of complete response and survival in nonseminomatous germ cell tumors. Cancer Res 50:5904-5910, 1990
28. Murphy BA, Motzer RJ, Mazumdar M, et al: Serum tumor marker decline is an early predictor of treatment outcome in germ cell tumor patients treated with cisplatin and ifoafamide salvage chemotherapy. Cancer 73:2520-2526, 1994
29. Motzer RJ, Mazumdar M, Gulati SC, et al: Phase II trial of high dose carboplatin and etoposide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors. J Natl Cancer Inst 85:1828-1835, 1993
30. See WA, Cohen MB, Hoxie LD: Alpha-fetoprotein half-life as a predictor of residual testicular tumor. Effect of the analytic strategy on test sensitivity and specificity. Cancer 71:2048-2054, 1993
31. Bosl GJ, Head MD: Serum tumor marker half-life during chemotherapy in patients with germ cell tumors. Int J Biol Markers 9:25-28, 1994
32. Stevens MJ, Norman AR, Dearnaley DP, et al: Prognostic significance of early serum tumor marker half-life in metastatic testicular teratoma. J Clin Oncol 13:87-92, 1995
33. de Wit R, Sylvester R, Tsitsa C, et al: Tumour marker concentration at the start of chemotherapy is a stronger predictor of treatment failure than marker half-life: A study in patients with disseminated non-seminomatous testicular cancer. Br J Cancer 75:432-435, 1997
34. Gerl A, Lamerz R, Clemm C, et al: Does serum tumor marker half-life complement pretreatment risk stratification in metastatic nonseminomatous germ cell tumors. Clin Cancer Res 2:1565-1570, 1996
35. Gerl A, Lemerz R, Mann K, et al: Is serum tumor marker half-life a guide to prognosis in metastatic nonseminomatous germ cell tumors? Anticancer Res 17:3047-3049, 1997
36. Inanc SE, Meral R, Darendeliler E, et al: Prognostic significance of marker half-life during chemotherapy in non-seminomatous germ cell testicular tumors. Acta Oncol 38:505-509, 1999
37. Mazumdar M, Bajorin DF, Bacik J, et al: Predicting outcome to chemotherapy in patients with germ cell tumors: The value of the rate of decline of human chorionic gonadotropin and al pha-fetoprotein during therapy. J Clin Oncol 19:2534-2541, 2001
38. Fizazi K, Kramar A, Culine S, et al: The early decline of tumor markers predicts outcome in poor-prognosis non-seminomatous germ-cell tumors (NSGCT): Results of a multi-institution study. Proc Am Soc Clin Oncol 21:185A, 2002 (abstr)
39. de Wit R, Collette L, Sylvester R, et al: Serum alpha-fetoprotein surge after the initiation of chemotherapy for non-seminomatous testicular cancer has an adverse prognostic significance. Br J Cancer 78:1350-1355, 1998
40. Samson MK, Rivkin SE, Jones SE, et al: Dose-response and dose-survival advantage for high versus low-dose cisplatin combined with vinblastine and bleomycin in disseminated testicular cancer. A Southwest Ontology Group study. Cancer 53:1029-1035, 1984
41. Nichols CR, Williams SD, Loehrer PJ, et al:. Randomized study of cisplatin dose intensity in poor-risk germ cell tumors: A Southeastern Cancer Study Group and Southwest Oncology Group protocol. J Clin Oncol 9:1163-1172, 1991
42. Loehrer PJ Sr, Lauer R, Roth BJ, et al: Salvage therapy in recurrent germ cell cancer: Ifosfamide and cisplatin plus either viriblastine or etoposide. Ann Intern Med 109:540-546, 1988
43. Nichols CR, Catalano PJ, Crawford ED, et al: Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: An Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B Study. J Clin Oncol 16:1287-1293, 1998
44. Wozniak AJ, Samson MK, Shah NT, et al: A randomized trial of cisplatin, vinblastine, and bleomycin versus vinblastine, cisplatin, and etoposide in the treatment of advanced germ cell tumors of the testis: A Southwest Oncology Group study. J Clin Oncol 9:70-76, 1991
45. de Wit R, Stoter G, Sleijfer DT, et al: Four cycles of BEP versus an alternating regime of PVB and BEP in patients with poorprognosis metastatic testicular non-seminoma; a randomised study of the EORTC Genitourinary Tract Cancer Cooperative Group. Br J Cancer 71:1311-1314, 1995
46. Lewis CR, Fossa SD, Mead G, et al: BOP/VIP - A new platinum-intensive chemotherapy regimen for poor prognosis germ cell tumours. Ann Oncol 2:203-211, 1991
47. Kaye SB, Mead GM, Fossa S, et al: Intensive induction-sequential chemotherapy with BOP/VIP-B compared with treatment with BEP/EP for poor-prognosis metastatic nonseminomatous germ cell tumor: A Randomized Medical Research Council/European Organization for Research and Treatment of Cancer study. J Clin Oncol 16:692-701, 1998
48. Bower M, Brock C, Holden L, et al: POMB/ACE chemotherapy for mediastinal germ cell tumours [see comments]. Eur J Cancer 33:838-842, 1997
49. Horwich A, Mason M, Fossa SD, et al: Accelerated induction chemotherapy (C-BOP-BEP) for poor and intermediate prognosis metastatic germ cell tumours. Proc Am Soc Clin Oncol 16:319A, 1997 (abstr)
50. Beyer J, Schwelia N, Zingsem J, et al: Hematopoietic rescue after high-dose chemotherapy using autologous peripheralblood progenitor cells or bone marrow: A randomized comparison. J Clin Oncol 13:1328-1335, 1995
51. Motzer RJ, Mazumdar M, Bosl GJ, et al. High-dose carboplatin, etoposide, and cyclophosphamide for patients with refractory germ cell tumors: Treatment results and prognostic factors for survival and toxicity. J Clin Oncol 14:1098-1105, 1996
52. Broun ER, Nichols CR, Turns M, et al: Early salvage therapy for germ cell cancer using high dose chemotherapy with autologous bone marrow support. Cancer 73:1716-1720, 1994
53. Motzer RJ, Mazumdar M, Bajorin DF, et al: High-dose carboplatin, etoposide and cyclophosphamide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors. J Clin Oncol 15:2546-2552, 1997
54. Chevreau C, Droz JP, Pico JL, et al: Early intensified chemotherapy with autologous bone marrow transplantation in first line treatment of poor risk non-seminomatous germ cell tumours. Preliminary results of a French randomized trial. Eur Urol 23:213-218, 1993
55. Droz JP, Pico JL, Ghosn M, et al: A phase 11 trial of early intensive chemotherapy with autologous bone marrow transplantation in the treatment of poor prognosis non seminomatous germ cell tumors Bull Cancer 79:497-507, 1992
56. Barnett MJ, Coppin CM, Murray N, et al: High-dose chemotherapy and autologous bone marrow transplantation for patients with poor prognosis nonseminomatous germ cell tumours. Br J Cancer 68:594-598, 1993
57. Schmoll HJ, Bokemeyer C: Sequential intermediate high-dose chemotherapy in the primary treatment of poor risk testicular cancer. Bone Marrow Transplant 18:S48-S49, 1996 (suppl 1)
58. Schmoll HJ, Bokemeyer C: The role of hemopoietic growth factors in the chemotherapy of germ cell tumors, in Horwich A: Testicular Cancer: Investigation and Management (2nd Ed). London, Chapman & Hall Medical, 1996, pp 295-306
59. Williams SD, Birch R, Greco FA, et al: Comparison of cisplatin + bleomycin + either vinblastine or VP-16 in disseminated testicular cancer: A preliminary report. Prog Clin Biol Res 153:219-223, 1984
60. Fossa SD, Kaye SB, Mead GM, et al: Filgrastim during combination chemotherapy of patients with poor-prognosis metastatic germ cell malignancy. European Organization for Research and Treatment of Cancer, Genito-Urinary Group, and the Medical Research Council Testicular Cancer Working Party, Cambridge, United Kingdom. J Clin Oncol 16:716-724, 1998
61. Murphy BR, Breeden ES, Donohue JP, et al: Surgical salvage of chemorefractory germ cell tumors. J Clin Oncol 11:324-329, 1993
62. deMent SH, Eggleston JC, Spivak JL: Association between mediastinal germ cell tumors and hematologic malignancies. Report of two cases and review of the literature. Am J Surg Pathol 9:23-30, 1985
63. Nichols CR, Hoffman R, Einhorn LH, et al: Hematologic malignancies associated with primary mediastinal germ-cell tumors. Ann Intern Med 102:603-609, 1985
64. Nichols CR, Heerema NA, Palmer C, et al: Klinefelter's syndrome associated with mediastinal germ cell neoplasms. J Clin Oncol 5:1290-1294, 1987
65. Dexeus FH, Logothetis CJ, Chong C, et al: Genetic abnormalities in men with germ cell tumors. J Urol 140:80-84, 1988
66. Saxman SB, Nichols CR, Einhom LH: Salvage chemotherapy in patients with extragonadal nonseminomatous germ cell tumors: The Indiana University experience. J Clin Oncol 12: 1390-1393, 1994
67. Beyer J, Kramar A, Mandanas R, et al: High-dose chemotherapy as salvage treatment in germ cell tumors: A multivariate analysis of prognostic variables. J Clin Oncol 14:2638-2645, 1996
68. Motzer RJ, Bosl GJ: Chemotherapy for germ cell tumors. Urol Clin North Am 14:389-398, 1987
69. Vuky J, Bains M, Bacik J, et al: Role of postchemotherapy adjunctive surgery in the management of patients with nonseminoma arising from the mediastinum. J Clin Oncol 19: 682-688, 2001
70. Kay PH, Wells FC, Goldstraw P: A multidisciplinary approach to primary nonseminomatous germ cell tumors of the mediastinum. Ann Thorac Surg 44:578-582, 1987
71. Vogelzang NJ, Raghavan D, Anderson RW, et al: Mediastinal nonseminomatous germ cell tumors: The role of combined modality therapy. Ann Thorac Surg 33:333-339, 1982
72. Fossa SD, Bokemeyer C, Gerl A, et al: Treatment outcome of patients with brain metastases from malignant germ cell tumors. Cancer 85:988-997, 1999
73. Rivoire M, Elias D, De Cian F, et al: Multimodality treatment of patients with liver metastases from germ cell tumors: The role of surgery. Cancer 92:578-587, 2001
74. Feuer EJ, Sheinfeld J, Bosl GJ: Does size matter? Association between number of patients treated and patient outcome in metastatic testicular cancer. J Natl Cancer Inst 91:816-818, 1999
75. Koberle B, Masters JR, Hartley JA, et al: Defective repair of cisplatin-induced DNA damage caused by reduced XPA protein in testicular germ cell tumours. Curr Biol 9:273-276, 1999
76. Schenkman NS, Sesterhenn IA, Washington L, et al: Increased p53 protein does not correlate to p53 gene mutations in microdissected human testicular germ cell tumors J. Urol 154: 617-621, 1995
77. Houldsworth J, Xiao H, Murty VV, et al: Human male germ cell tumor resistance to cisplatin is linked to TP53 gene mutation Oncogene 16:2345-2349, 1998
78. Rao PH, Houldsworth J, Palanisamy N, et al: Chromosomal amplification is associated with cisplatin resistance of human male germ cell tumors. Cancer Res 58:4260-4263, 1998
79. Horwich A, Dearnaley DP, Norman A, et al: Accelerated chemotherapy for poor prognosis germ cell tumours. Eur J Cancer 30A:1607-1611, 1994
80. Newlands ES, Begent RH, Rustin GJ, et al: Further advances in the management of malignant teratomas of the testis and other sites. Lancet 1:948-951, 1983
81. Hitchins RN, Newlands ES, Smith DB, et al: Long-term outcome in patients with germ cell tumours treated with POMB/ACE chemotherapy: Comparison of commonly used classification systems of good and poor prognosis. Br J Cancer 59: 236-242, 1989
82. Bower M, Holden L, Rustin GJS, et al: POMB/ACE chemotherapy for advanced non-seminomatous germ cell tumours in men. Proc Am Soc Clin Oncol 16:319A, 1997 (abstr)
83. de Wit R, Louwerens M, de Mulder PH, et al: Management of intermediate-prognosis germ-cell cancer: Results of a phase 1/11 study of Taxol-BEP. Int J Cancer 83:831-833, 1999
84. Motzer RJ, Chou TC, Schwartz L, et al: Paclitaxel in germ cell cancer. Semin Oncol 22:12-15, 1995